Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Open Orphan Plc ( (GB:HVO) ) has shared an update.
hVIVO plc has appointed Shaun Chilton as the new Non-Executive Chair of its Board of Directors, effective immediately. Shaun Chilton, who brings over 30 years of experience in leading and managing both private and public businesses, is expected to support hVIVO in its growth and diversification strategy. His previous roles include CEO of Clinigen Group plc and various board positions in UK public companies. This appointment is seen as a strategic move to enhance hVIVO’s leadership as it continues to expand its service offerings and maintain its position as a leader in human challenge trials.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £11.50 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on GB:HVO Stock
According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.
The overall stock score reflects strong valuation and financial performance, with a low P/E ratio and robust revenue growth. However, technical analysis indicates bearish trends, which slightly offset the positive valuation and financial metrics. The absence of earnings call data means corporate events were not factored into the score, although they present a positive outlook.
To see Spark’s full report on GB:HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service Contract Research Organisation (CRO) and a global leader in human challenge trials. The company provides comprehensive clinical development services to a wide range of clients, including seven of the world’s ten largest biopharma companies. Specializing in human challenge trials for infectious and respiratory diseases, hVIVO operates the largest quarantine facility in London and offers extensive virology and immunology laboratory services. Through its subsidiaries, CRS and Venn Life Sciences, hVIVO delivers early-phase clinical trial services and drug development consulting, ensuring a seamless transition from preclinical stages to late-stage development.
Average Trading Volume: 2,405,094
Technical Sentiment Signal: Sell
Current Market Cap: £68.01M
For a thorough assessment of HVO stock, go to TipRanks’ Stock Analysis page.